P2Y14R for inflammation therapy: is it a promising target?

Future Med Chem. 2021 Sep;13(18):1493-1495. doi: 10.4155/fmc-2021-0084. Epub 2021 Jul 19.

Authors

Yuyang Wang^{1

2}, Yongtao Duan¹

Affiliations

¹ Henan Provincial Key Laboratory of Children's Genetics & Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, 450018, PR, China.
² School of Pharmaceutical Science, Zhengzhou University, Zhengzhou, 450001, PR, China.

PMID: 34278830
DOI: 10.4155/fmc-2021-0084

No abstract available

Keywords: P2Y14R; UDP; antagonists; inflammation; nucleotide.

Publication types

Editorial

MeSH terms

Anti-Inflammatory Agents / chemistry*
Anti-Inflammatory Agents / pharmacology
Benzofurans / chemistry
Benzoic Acid / chemistry
Biomarkers / metabolism*
Drug Evaluation, Preclinical
Humans
Inflammation / drug therapy*
Naphthalenes / chemistry
Purinergic P2 Receptor Antagonists / chemistry*
Purinergic P2 Receptor Antagonists / pharmacology
Pyrimidines / chemistry
Receptors, Purinergic P2 / metabolism*
Structure-Activity Relationship
Triazoles / chemistry

Substances

Anti-Inflammatory Agents
Benzofurans
Biomarkers
Naphthalenes
P2Y14 receptor, human
Purinergic P2 Receptor Antagonists
Pyrimidines
Receptors, Purinergic P2
Triazoles
Benzoic Acid
pyrimidine
benzofuran
2-naphthoic acid